Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

ClinicalTrials.gov ID: NCT05702229

Public ClinicalTrials.gov record NCT05702229. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

Study identification

NCT ID: NCT05702229
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: AstraZeneca; Industry
Enrollment: 163 participants

Conditions and interventions

Conditions

Gastric Cancer

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 15, 2023
Primary completion: Nov 29, 2027
Completion: May 30, 2029
Last update posted: May 13, 2026

2023 – 2029

United States locations

U.S. sites: 11
U.S. states: 5
U.S. cities: 8

Facility	City	State	ZIP	Site status
Research Site	Los Angeles	California	90017	Recruiting
Research Site	Los Angeles	California	90095	Withdrawn
Research Site	Baton Rouge	Louisiana	70817	Recruiting
Research Site	Grand Rapids	Michigan	49503	Recruiting
Research Site	New Hyde Park	New York	11042	Withdrawn
Research Site	New York	New York	10028	Withdrawn
Research Site	New York	New York	10065	Recruiting
Research Site	New York	New York	11210	Withdrawn
Research Site	Shirley	New York	11967	Withdrawn
Research Site	The Bronx	New York	10469	Withdrawn
Research Site	Pittsburgh	Pennsylvania	15212	Withdrawn

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05702229, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 13, 2026 · Synced Sep 1, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05702229 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →